Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.71 |
| ▸ | NOS1 | P29475 | 9/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29776986 | 0.85 | HSD17B10 (0.85) | HSD17B10NOS1KDM4EALDH1A1MEN1 | |
| SCHEMBL5541270 | 0.85 | HSD17B10 (0.85) | HSD17B10NOS1KDM4EALDH1A1MEN1 | |
| SCHEMBL258468 | 0.85 | HSD17B10 (0.85) | HSD17B10NOS1KDM4EALDH1A1MEN1 | |
| SCHEMBL29400382 | 0.85 | HSD17B10 (0.85) | HSD17B10NOS1KDM4EALDH1A1MEN1 | |
| SCHEMBL13947293 | 0.85 | HSD17B10 (0.85) | HSD17B10NOS1KDM4EALDH1A1MEN1 | |
| SCHEMBL29776929 | 0.85 | HSD17B10 (0.85) | HSD17B10NOS1KDM4EALDH1A1MEN1 | |
| SCHEMBL15144421 | 0.85 | HSD17B10 (0.85) | HSD17B10NOS1KDM4EALDH1A1MEN1 | |
| SCHEMBL24811788 | 0.82 | NOS1 (0.60) | HSD17B10NOS1KDM4EALDH1A1MEN1 | |
| SCHEMBL24574329 | 0.81 | HSD17B10 (0.67) | HSD17B10NOS1KDM4EALDH1A1MEN1 | |
| SCHEMBL23028910 | 0.81 | HSD17B10 (0.67) | HSD17B10NOS1KDM4EALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, FCGR3B, FCGR2A | HSD17B10 4659/4885NOS1 4318/4885KDM4E 4323/4885 |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, ASGR1, FCGR3B | HSD17B10 4755/4885NOS1 4179/4885KDM4E 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.